Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.


Sci. STKE, 25 April 2006
Vol. 2006, Issue 332, p. tw140
[DOI: 10.1126/stke.3322006tw140]

EDITORS' CHOICE

PHARMACOLOGY From in Silico to in Vitro Drug Discovery

Many currently available therapeutic drugs act by modulating signaling through G protein (heterotrimeric GTP-binding protein)-coupled receptors. The G protein β{gamma} subunit transmits signals from G protein-coupled receptors to target proteins, and many crystal structures of such complexes have been solved. Bonacci et al. (see the Perspective by Tesmer) used a computer program to predict which chemical compounds would bind to the interaction site on the β{gamma} subunits and obtained potent small-molecule inhibitors of protein-protein interactions. Furthermore, these molecules showed specificity for disrupting signaling-specific downstream targets, which suggests that such reagents might be both effective and relatively free of side effects.

T. M. Bonacci, J. L. Mathews, C. Yuan, D. M. Lehmann, S. Malik, D. Wu, J. L. Font, J. M. Bidlack, A. V. Smrcka, Differential targeting of Gβ{gamma}-subunit signaling with small molecules. Science 312, 443-446 (2006). [Abstract] [Full Text]

J. J. G. Tesmer, Hitting the hot spots of cell signaling cascades. Science 312, 377-378 (2006). [Summary] [Full Text]

Citation: From in Silico to in Vitro Drug Discovery. Sci. STKE 2006, tw140 (2006).



To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882